Chronic Thromboembolic Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery o...
Gespeichert in:
Veröffentlicht in: | Lung 2022-06, Vol.200 (3), p.283-299 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 299 |
---|---|
container_issue | 3 |
container_start_page | 283 |
container_title | Lung |
container_volume | 200 |
creator | Teerapuncharoen, Krittika Bag, Remzi |
description | Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH. |
doi_str_mv | 10.1007/s00408-022-00539-w |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2672323337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A707515283</galeid><sourcerecordid>A707515283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</originalsourceid><addsrcrecordid>eNp9kV1LHDEYhUOx1NX2D_RCBKF4E_smmXzspSytCkJ7sfdhMvPO7kgmWZMZxH9vtmv9KEsJ4SXJcw7hHEK-MrhgAPp7BqjAUOCcAkgxpw8fyIxVglOmJRyQGYiKUV6gQ3KU8x0A04rJT-RQSFUJA3xG6GKdYuib02WZg4tYti_H35MfYqjT4-n14wbTiCH3MXwmH7vaZ_zyPI_J8ueP5eKa3v66ullc3tJGgh4pcxW6DmEu0SjX6lYCcq5M67oKWmjnkjllQFXGKKUMa5lylZSGK46mceKYnO9sNyneT5hHO_S5Qe_rgHHKlivNBRdC6IKe_YPexSmF8rktZUALweev1Kr2aPvQxTHVzdbUXmrQkkluRKHoHmqFAVPtY8CuL9fv-Is9fFktDn2zV_DtjWCNtR_XOfppLNHm9yDfgU2KOSfs7Cb1Q2nDMrDb7u2ue1u6t3-6tw9FdPIcxeQGbF8kf8sugNgBuTyFFabXrP5j-wTNybUj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2678073329</pqid></control><display><type>article</type><title>Chronic Thromboembolic Pulmonary Hypertension</title><source>SpringerLink Journals</source><creator>Teerapuncharoen, Krittika ; Bag, Remzi</creator><creatorcontrib>Teerapuncharoen, Krittika ; Bag, Remzi</creatorcontrib><description>Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.</description><identifier>ISSN: 0341-2040</identifier><identifier>EISSN: 1432-1750</identifier><identifier>DOI: 10.1007/s00408-022-00539-w</identifier><identifier>PMID: 35643802</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Angiography ; Angioplasty ; Anticoagulants ; Balloon treatment ; Care and treatment ; Computed tomography ; CT imaging ; Diagnosis ; Dyspnea ; Embolism ; Health aspects ; Hypertension ; Intolerance ; Medicine ; Medicine & Public Health ; Occlusion ; Patients ; Perfusion ; Pneumology/Respiratory System ; Pulmonary arteries ; Pulmonary artery ; Pulmonary embolism ; Pulmonary embolisms ; Pulmonary hypertension ; Respiration ; State of the Art Review ; Thromboembolism</subject><ispartof>Lung, 2022-06, Vol.200 (3), p.283-299</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</citedby><cites>FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</cites><orcidid>0000-0003-4804-3088 ; 0000-0001-8313-6015</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00408-022-00539-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00408-022-00539-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35643802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Teerapuncharoen, Krittika</creatorcontrib><creatorcontrib>Bag, Remzi</creatorcontrib><title>Chronic Thromboembolic Pulmonary Hypertension</title><title>Lung</title><addtitle>Lung</addtitle><addtitle>Lung</addtitle><description>Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.</description><subject>Angiography</subject><subject>Angioplasty</subject><subject>Anticoagulants</subject><subject>Balloon treatment</subject><subject>Care and treatment</subject><subject>Computed tomography</subject><subject>CT imaging</subject><subject>Diagnosis</subject><subject>Dyspnea</subject><subject>Embolism</subject><subject>Health aspects</subject><subject>Hypertension</subject><subject>Intolerance</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Occlusion</subject><subject>Patients</subject><subject>Perfusion</subject><subject>Pneumology/Respiratory System</subject><subject>Pulmonary arteries</subject><subject>Pulmonary artery</subject><subject>Pulmonary embolism</subject><subject>Pulmonary embolisms</subject><subject>Pulmonary hypertension</subject><subject>Respiration</subject><subject>State of the Art Review</subject><subject>Thromboembolism</subject><issn>0341-2040</issn><issn>1432-1750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kV1LHDEYhUOx1NX2D_RCBKF4E_smmXzspSytCkJ7sfdhMvPO7kgmWZMZxH9vtmv9KEsJ4SXJcw7hHEK-MrhgAPp7BqjAUOCcAkgxpw8fyIxVglOmJRyQGYiKUV6gQ3KU8x0A04rJT-RQSFUJA3xG6GKdYuib02WZg4tYti_H35MfYqjT4-n14wbTiCH3MXwmH7vaZ_zyPI_J8ueP5eKa3v66ullc3tJGgh4pcxW6DmEu0SjX6lYCcq5M67oKWmjnkjllQFXGKKUMa5lylZSGK46mceKYnO9sNyneT5hHO_S5Qe_rgHHKlivNBRdC6IKe_YPexSmF8rktZUALweev1Kr2aPvQxTHVzdbUXmrQkkluRKHoHmqFAVPtY8CuL9fv-Is9fFktDn2zV_DtjWCNtR_XOfppLNHm9yDfgU2KOSfs7Cb1Q2nDMrDb7u2ue1u6t3-6tw9FdPIcxeQGbF8kf8sugNgBuTyFFabXrP5j-wTNybUj</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Teerapuncharoen, Krittika</creator><creator>Bag, Remzi</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4804-3088</orcidid><orcidid>https://orcid.org/0000-0001-8313-6015</orcidid></search><sort><creationdate>20220601</creationdate><title>Chronic Thromboembolic Pulmonary Hypertension</title><author>Teerapuncharoen, Krittika ; Bag, Remzi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-1b4ebfe095e86bd7d50e2268dbf40d0d951b680648866681d16b4558262e8cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angiography</topic><topic>Angioplasty</topic><topic>Anticoagulants</topic><topic>Balloon treatment</topic><topic>Care and treatment</topic><topic>Computed tomography</topic><topic>CT imaging</topic><topic>Diagnosis</topic><topic>Dyspnea</topic><topic>Embolism</topic><topic>Health aspects</topic><topic>Hypertension</topic><topic>Intolerance</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Occlusion</topic><topic>Patients</topic><topic>Perfusion</topic><topic>Pneumology/Respiratory System</topic><topic>Pulmonary arteries</topic><topic>Pulmonary artery</topic><topic>Pulmonary embolism</topic><topic>Pulmonary embolisms</topic><topic>Pulmonary hypertension</topic><topic>Respiration</topic><topic>State of the Art Review</topic><topic>Thromboembolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teerapuncharoen, Krittika</creatorcontrib><creatorcontrib>Bag, Remzi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Lung</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teerapuncharoen, Krittika</au><au>Bag, Remzi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic Thromboembolic Pulmonary Hypertension</atitle><jtitle>Lung</jtitle><stitle>Lung</stitle><addtitle>Lung</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>200</volume><issue>3</issue><spage>283</spage><epage>299</epage><pages>283-299</pages><issn>0341-2040</issn><eissn>1432-1750</eissn><abstract>Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation–perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35643802</pmid><doi>10.1007/s00408-022-00539-w</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-4804-3088</orcidid><orcidid>https://orcid.org/0000-0001-8313-6015</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0341-2040 |
ispartof | Lung, 2022-06, Vol.200 (3), p.283-299 |
issn | 0341-2040 1432-1750 |
language | eng |
recordid | cdi_proquest_miscellaneous_2672323337 |
source | SpringerLink Journals |
subjects | Angiography Angioplasty Anticoagulants Balloon treatment Care and treatment Computed tomography CT imaging Diagnosis Dyspnea Embolism Health aspects Hypertension Intolerance Medicine Medicine & Public Health Occlusion Patients Perfusion Pneumology/Respiratory System Pulmonary arteries Pulmonary artery Pulmonary embolism Pulmonary embolisms Pulmonary hypertension Respiration State of the Art Review Thromboembolism |
title | Chronic Thromboembolic Pulmonary Hypertension |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T13%3A18%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20Thromboembolic%20Pulmonary%20Hypertension&rft.jtitle=Lung&rft.au=Teerapuncharoen,%20Krittika&rft.date=2022-06-01&rft.volume=200&rft.issue=3&rft.spage=283&rft.epage=299&rft.pages=283-299&rft.issn=0341-2040&rft.eissn=1432-1750&rft_id=info:doi/10.1007/s00408-022-00539-w&rft_dat=%3Cgale_proqu%3EA707515283%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2678073329&rft_id=info:pmid/35643802&rft_galeid=A707515283&rfr_iscdi=true |